Zymenex has – with the financial support of BankInvest Biomedical Venture and Sunstone Capital – achieved successful early clinical development of a therapeutic candidate Metazym against the rare, lethal and genetically caused, disease MLD, which most often affects children at a very young age. This has now resulted in a sale of the therapeutic project to the global specialty biopharmaceutical company Shire plc.

Shire plc, which is quoted on the London Stock Exchange and Nasdaq, is one of the world’s largest specialty biopharmaceutical companies. Shire expects - after the acquisition of the Metazym project – to continue development and to seek to bring the product to market as quickly as possible.

Shire delivers – upon receipt of customary consents - 135 million USD to Zymenex in an upfront payment for global rights to the Metazym clinical candidate. Zymenex, headquartered in Hillerød, Denmark, is a privately owned company with BankInvest Biomedical Venture and Sunstone Capital as the largest shareholders.